patient subgroup...
age >= 55 yr age >= 65 yr critical disease omicron variant BA.1 (B.1.1.529) solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Immunostimulants drugs - versus placebo - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.76 [0.61, 0.95]< 1 0% 7 studies (7/-) 99.2 % some concern not evaluable moderate crucial - death or transfer to ICU 0.65 [0.35, 1.22]< 1 0% 1 study (1/-) 90.9 % NA not evaluable crucial - deaths 0.78 [0.66, 0.92]< 1 0% 16 studies (16/-) 99.8 % some concern low moderate crucial - deaths (time to event analysis only) 0.83 [0.64, 1.07]< 1 0% 6 studies (6/-) 92.4 % some concern serious moderate crucial - clinical deterioration 0.71 [0.44, 1.13]< 1 55% 3 studies (3/-) 92.5 % some concern not evaluable moderate important - clinical improvement 1.05 [0.96, 1.15]> 1 14% 9 studies (9/-) 84.5 % some concern not evaluable moderate important - clinical improvement (14-day) 1.01 [0.79, 1.29]> 1 0% 1 study (1/-) 53.2 % NA not evaluable important - clinical improvement (28-day) 1.77 [0.94, 3.32]> 1 35% 3 studies (3/-) 96.3 % some concern not evaluable moderate important - clinical improvement (7-day) 0.98 [0.76, 1.26]> 1 0% 2 studies (2/-) 43.1 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.01 [0.91, 1.13]> 1 0% 4 studies (4/-) 59.1 % some concern not evaluable moderate important - death or ventilation 0.64 [0.45, 0.90]< 1 0% 2 studies (2/-) 99.4 % some concern not evaluable moderate important - hospital discharge 1.21 [0.85, 1.72]> 1 58% 3 studies (3/-) 85.3 % low not evaluable high important - hospitalization 1.00 [0.14, 7.34]< 1 0% 1 study (1/-) 50.0 % NA not evaluable important - mechanical ventilation 1.03 [0.53, 2.00]< 1 0% 2 studies (2/-) 46.4 % low not evaluable high important - viral clearance 0.81 [0.56, 1.18]> 1 0% 1 study (1/-) 13.7 % NA not evaluable important - viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 1 0% 1 study (1/-) 13.7 % NA not evaluable important - ICU admission 0.60 [0.33, 1.10]< 1 0% 2 studies (2/-) 95.1 % some concern not evaluable moderate non important - recovery 1.12 [0.97, 1.28]> 1 7% 4 studies (4/-) 94.3 % low not evaluable high non important - 00 composite safety outcome 1.56 [0.78, 3.11]< 1 0% 1 study (1/-) 10.3 % NA not evaluable important - serious adverse events 0.97 [0.71, 1.33]< 1 10% 4 studies (4/-) 57.8 % some concern not evaluable moderate important - adverse events 1.33 [0.63, 2.78]< 1 0% 1 study (1/-) 22.7 % NA not evaluable non important -
LoD: level of statistical demonstration:
